352 related articles for article (PubMed ID: 26604011)
1. Harnessing adaptive natural killer cells in cancer immunotherapy.
Liu LL; Pfefferle A; Yi Sheng VO; Björklund AT; Béziat V; Goodridge JP; Malmberg KJ
Mol Oncol; 2015 Dec; 9(10):1904-17. PubMed ID: 26604011
[TBL] [Abstract][Full Text] [Related]
2. Deciphering Natural Killer Cell Homeostasis.
Pfefferle A; Jacobs B; Haroun-Izquierdo A; Kveberg L; Sohlberg E; Malmberg KJ
Front Immunol; 2020; 11():812. PubMed ID: 32477340
[TBL] [Abstract][Full Text] [Related]
3. Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.
Tarazona R; Sanchez-Correa B; Casas-Avilés I; Campos C; Pera A; Morgado S; López-Sejas N; Hassouneh F; Bergua JM; Arcos MJ; Bañas H; Casado JG; Durán E; Labella F; Solana R
Cancer Immunol Immunother; 2017 Feb; 66(2):233-245. PubMed ID: 27530271
[TBL] [Abstract][Full Text] [Related]
4. Memory-like natural killer cells for cancer immunotherapy.
Gang M; Wong P; Berrien-Elliott MM; Fehniger TA
Semin Hematol; 2020 Oct; 57(4):185-193. PubMed ID: 33256911
[TBL] [Abstract][Full Text] [Related]
5. Current progress in cancer immunotherapy based on natural killer cells.
Bagheri Y; Barati A; Aghebati-Maleki A; Aghebati-Maleki L; Yousefi M
Cell Biol Int; 2021 Jan; 45(1):2-17. PubMed ID: 32910474
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell engineering - a new hope for cancer immunotherapy.
Lin CY; Gobius I; Souza-Fonseca-Guimaraes F
Semin Hematol; 2020 Oct; 57(4):194-200. PubMed ID: 33256912
[TBL] [Abstract][Full Text] [Related]
7. Harnessing NK Cells for Cancer Treatment.
Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
Front Immunol; 2019; 10():2836. PubMed ID: 31867006
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological targeting of natural killer cells for cancer immunotherapy.
Miyazato K; Hayakawa Y
Cancer Sci; 2020 Jun; 111(6):1869-1875. PubMed ID: 32301190
[TBL] [Abstract][Full Text] [Related]
9. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
10. The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy.
Souza-Fonseca-Guimaraes F; Cursons J; Huntington ND
Trends Immunol; 2019 Feb; 40(2):142-158. PubMed ID: 30639050
[TBL] [Abstract][Full Text] [Related]
11.
Liu LL; Béziat V; Oei VYS; Pfefferle A; Schaffer M; Lehmann S; Hellström-Lindberg E; Söderhäll S; Heyman M; Grandér D; Malmberg KJ
Cancer Immunol Res; 2017 Aug; 5(8):654-665. PubMed ID: 28637877
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cells: the journey from puzzles in biology to treatment of cancer.
Bodduluru LN; Kasala ER; Madhana RM; Sriram CS
Cancer Lett; 2015 Feb; 357(2):454-67. PubMed ID: 25511743
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell biology: an update and future directions.
Campbell KS; Hasegawa J
J Allergy Clin Immunol; 2013 Sep; 132(3):536-544. PubMed ID: 23906377
[TBL] [Abstract][Full Text] [Related]
15. Leukocyte Immunoglobulin-Like Receptor 1-Expressing Human Natural Killer Cell Subsets Differentially Recognize Isolates of Human Cytomegalovirus through the Viral Major Histocompatibility Complex Class I Homolog UL18.
Chen KC; Stanton RJ; Banat JJ; Wills MR
J Virol; 2016 Jan; 90(6):3123-37. PubMed ID: 26739048
[TBL] [Abstract][Full Text] [Related]
16. Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient Humans.
Liu LL; Landskron J; Ask EH; Enqvist M; Sohlberg E; Traherne JA; Hammer Q; Goodridge JP; Larsson S; Jayaraman J; Oei VYS; Schaffer M; Taskén K; Ljunggren HG; Romagnani C; Trowsdale J; Malmberg KJ; Béziat V
Cell Rep; 2016 May; 15(5):1088-1099. PubMed ID: 27117418
[TBL] [Abstract][Full Text] [Related]
17. Late Development of FcεRγ
Muccio L; Falco M; Bertaina A; Locatelli F; Frassoni F; Sivori S; Moretta L; Moretta A; Della Chiesa M
Front Immunol; 2018; 9():1050. PubMed ID: 29868012
[TBL] [Abstract][Full Text] [Related]
18. [Natural killer (NK) cell and immunotherapy].
Iino T; Takaishi S
Nihon Rinsho; 2017 Feb; 75(2):306-311. PubMed ID: 30562869
[TBL] [Abstract][Full Text] [Related]
19. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
20. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy.
Wolf NK; Kissiov DU; Raulet DH
Nat Rev Immunol; 2023 Feb; 23(2):90-105. PubMed ID: 35637393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
